Description du projet
Un modèle de ganglion lymphatique 3D bio-imprimé pour la découverte de médicaments
Plus de 90 % des médicaments oncologiques ne passent pas les essais cliniques. Cela est dû au fait que les modèles in vitro utilisés pour la découverte de médicaments ne sont pas fiables. Le projet 3DLT, financé par l’UE, vise à commercialiser une technologie exclusive de bio-impression 3D utilisant des cellules humaines vivantes pour générer des tissus qui ressemblent étroitement à leurs équivalents humains. Les chercheurs ont développé un ganglion lymphatique 3D sous forme de plateforme pour tester de nouvelles immunothérapies contre le cancer. Parmi les travaux du projet se trouvent l’évaluation de la faisabilité économique concernant la commercialisation du produit ainsi que la conclusion des partenariats commerciaux et industriels nécessaires pour atteindre cet objectif.
Objectif
Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
43122 PARMA
Italie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.